{
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "患有幽闭恐惧症和IBS或没有资格接受初级或二级审判的妇女。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有需要满足的精神心理健康、体重、肿瘤大小、Karnofsky/ECOG得分或估计预期寿命条件才能有资格接受初级审判的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "第二次审判要求病人超过一定年龄,但初级审判没有规定参与的年龄范围。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加二级审判的病人没有资格同时参加初级审判",
        "Label": "Entailment",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + 初级审判中的病人在整个审判期间得到与二级审判第2组第2组病人一样的创伤性创伤剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "初级审判或二级审判的Aes没有记录有厌食、低温或幻觉。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "如果病人在上个月内接受了器官移植手术,并且仍然卧床不起床,将被排除在初级审判之外,但可能有资格接受二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何患甲状腺素过敏或三甲基甲状腺素/舒尔法新诺明的有文件证明的甲状腺素过敏症患者将不符合第二次试验资格,而患甲状腺素或丙烯氧素过敏的有文件证明的甲状腺素过敏症患者也将被排除在初级试验之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级审判的干预是通过不同途径实施的。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "新诊断为第四阶段乳腺癌(经确认为ER+)妇女患乳腺癌的新诊断四级妇女,考虑到胎儿切除术有资格接受初级和二级审判",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "具有经精神学确认的第四阶段乳腺癌患者,如果是ER阳性、PR阳性或HER2负性,则有资格接受二审和初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二级审判和初级审判结果包含完全不同的结果措施",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验参与者不接受任何疫苗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "初级审判组A和B的Cohort A和B同样使用三注射LD V934的电动注射器。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "第二次审判和初级审判的结果采用不同的计量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "初级审判组的结果没有重大差别,二级审判的反灵活学组和控制组得出的结果相同。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "TAK-228+Tamoxifen初级试验6周以上TAK-228+Tamoxifen治疗病人在基67表示值的细胞百分比下降5%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级审判的第2号臂比第1号臂的操作时间要长,因此,在这方面,手术内乳房造影的性能比标准乳房造影法要好,在二级审判中,我们无法比较对照对照组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "初级审判第1组记录了几起与心脏相关的性能AE的几起不同案例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级审判和二级审判的病人患有血栓塞症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "在初级审判中,所有二级审判中的干预药物都必须静脉注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级审判中,肝中毒病例数是肝中毒病例数的10倍,因为有高血压和血管切除手术病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "仅具备有限自我照顾能力的候选人;被限制在床上或坐在椅子上,觉醒时间超过50%,既有资格接受初级审判,也有资格接受二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级审判的合议庭1号没有报告任何Aes族人,但几乎所有第2组候选人都至少有1名Ae",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "过去两周接受化疗或放射治疗、患有不稳定的心血管炎、或患有二级或二级以上神经病的病人不能参加第二次审判,但可以继续参加初级审判,除非他们有不愈合的外科伤口。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "第二次审判候选人必须满足一定的绩效状况条件才能参加,而不需要接受这一条件进入初级审判",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "冠状动脉加速症是初级审判中记录的最常见的ACE",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "对初级审判的干预包括一种药物,而在二级审判中,干预至少需要三种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "患有前期和时期痴呆或混合痴呆症的患者有资格接受初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ]
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级审判的两个审判组的参加人数相同",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            13
        ]
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "有肺栓塞史的病人和目前有乳房植入的病人不能参加第二次或第一次试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "初级审判的不利事件总数少于二级审判,但初级审判的心脏病/心脏病病例多于二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初试病人需要在研究的第8天一次性注射一次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "初级试验2组:0.5微克/千克的近视(5毫升),二级试验组的病人没有接受任何近视。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "对2-3脑转移的诊断将导致被排斥在二级审判之外,然而,接受这种诊断的病人仍可能是初级审判的Eligilbe。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "被诊断患有浸泡乳腺癌的病人没有资格接受初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ]
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "在过去一年中,先前在Gabapentin或雌激素治疗后,将被排除在二审之外,但不会被排除在初级审判之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            18
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级审判中,安慰剂干预和曼庭干预都每天一次口头管理一次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "禁止初级审判候选人接受基于酷刑的治疗,但他们可能仍然有资格参加第二次审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7名初级审判参与者,0/1674名二级审判参与者获得共同申请。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "初级审判的第2组第2组通过口头对Enzalutamide进行口头管理,而第1组则在第四组进行复述。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "过去三年内患有肺栓塞的病人被排除在初级审判之外,但根据调查员的决定,可能有资格接受二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "在进行大约7个月的研究后,在初级试验的两组中,有三分之一以上的患者在乳房和轴心淋巴结结中都经历过病理学全面反应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "初级审判中的第2臂比第1臂的操作时间高,因此,控制组在这方面的表现优于试验组。 在二级审判中,我们无法比较对照组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "在审判期间的几个点上,初级审判中的病人得到与二级审判第2组病人同样的创伤性创伤剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "只有三种不同类型的不利事件在初级试验中影响病人,即肺炎、霍乱、肝疼痛和二月肺炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "在初级审判中至少有一名病人遭受了几次不同的不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "在初级试验中,患者的淋巴肿变化优于睾丸激素Cream患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在二审病人中观察到的唯一类型的Aes是在二审病人中观察到的唯一类型的Aes,即眼皮水肿、上胃肠胃出血和胸痛,在一审中没有Aes记录。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级审判第1组第1组适用PR阴性、ER阴性、ER阴性,而第2组接受HER2+",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "在初级试验期间,使用激光辅助荧光血管造影术进行两次干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "273名主要审判参与者和0/1674名二级审判参与者患有急性心肌梗塞",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级审判正在评估遭受与不良事件有关的治疗的病人人数,而二级审判则在分钟内衡量其病人的中位睡眠时间。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级审判的第一组第一组将教育DVD视视视视教育DVD为干预的一部分,而Cohort 2将定期接受放射治疗的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级审判采用一个月的干预周期,而二级审判则没有进行周期性治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "当地诊断患有Ductal恶性肿瘤的病人,如果正在接受AI疗法治疗,则有资格接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "初级审判的每个参与者都接受同样的干预,不管他们是否患有癌症。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级审判的两组组人在整个审判期间以同一频率获得多克萨斯、多克索罗比辛和氯二苯丙胺的同样剂量,但第二组人包括三个特殊药物的额外治疗周期。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在初级审判和二级审判中,有超过30%的参与者发生了几次不利事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "主要试用候选人不常见饮食紊乱症",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7
        ]
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "只有特定国籍的女病人才能参加初级审判,参加二级审判不需要这种条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "初级审判干预包括利用TheraSpheres进行放射性破灭,另一方面,二级审判干预则以ibrutinib和MEDI4736为基础。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级审判和二级审判记录了0起不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初级和二级初审中,15%以上的患者在研究期内感染了传染病",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "对脑电图内2-3脑转移进行诊断后,将被排除在第二次试验之外,但是,接受这种诊断的病人仍可能是初级试验的免疫素。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            6,
            1,
            2
        ],
        "Secondary_evidence_index": [
            13
        ]
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "第二次审判中最常见的不利事件是贫血,影响5%以上的病人,在初级审判中没有记录到AEs。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "在10周的研究中,在初试期间,一些病人没有任何疼痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "任何患有重大或不受控制心血管障碍的病人都不得参加初级或二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "在原地确诊患有恶性肺癌的病人有资格接受第二次审判,但被排除在初级审判之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "所有在初级试验中接受安慰剂干预的病人均经历过败血症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            10,
            11,
            6,
            7,
            8,
            15
        ]
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何被诊断患有癫痫、血清综合症或贫血症的癌症患者,都无资格接受初级和二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "作为干预措施的一部分,一些初级审判候选人每天经管1 000立方米的talazoparibt",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "初级审判的第1组和第2组获得CUDC-101的同样剂量,但第1组更经常地接受CUDC-101的管理。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "初级审判使用3周周期进行干预,而二级审判则没有进行周期治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "每个接受初级试验的病人在放射治疗期间都接受100至1600   g fentanyl 亚语言喷雾的剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "初级审判中的感染、非对称和恶心案件多于二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "患有第4阶段癌症的病人,如果提供知情同意,则有资格接受第二次审判和第一次审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级审判和二级审判都使用pCR作为结果衡量标准,初级审判的两个组别的结果略有不同,而在二级审判中,Arm 2比第1组的结果好得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "除了一人外,在初审中接受过Sunitinib + Docexaxel + Trastuzumab治疗的所有病人都遭受了治疗紧急不利事件,不到一半的病人遭受严重治疗紧急不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "使用同一计量单位进行二审和首审报告结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级审判和二级审判记录了其组群的100多起全部不利事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "安慰剂和创伤性病对初级审判的干预都是通过每两周一次的3小时静脉注射进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "患有第4阶段癌症的病人没有资格接受第二次审判,但他们有资格接受初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "初级审判第2组第2组的剂量比第1组的安扎卢塔米德剂量高出一倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "过去两周接受化疗或放射治疗、患有不稳定的心血管炎、或患有二级或二级以上神经病的病人不能参加第二次审判,但如果他们符合所有相关的包容标准,仍可以参加初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            14,
            15,
            23,
            24,
            27
        ]
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "初级审判记录的任何个别不利事件类型都没有影响到一个以上的病人",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "过去6个月内,患者如果想参加初级试验,就不能有腹腔瘘、胃肠道穿孔、骨质绝经、肾上癌、中风、短暂性缺血性袭击、腹部内出血或重大精神紊乱的历史。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            11,
            19,
            1
        ]
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "年满18岁或18岁以上的妇女有资格接受二审和一审",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "在初级审判中,共有35名病人接受了Sunitinib + Docexaxel + Trastuzumab的治疗,并遭受了紧急治疗不良事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "在初级试验中,没有一个病人在10周的时间里经历了可以想象的最痛苦。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "第二次试验病人患贫血、肺炎和眩晕的频率高于初级试验病人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "在初级审判中,一名病人在手术后手术切口重新开刀。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ]
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验的AZD0530175毫克组第4周乙型CTX的百分率变化大于Zoledronic酸4毫克组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "初级审判参与者中不到10%的初级审判参与者的循环肿瘤细胞数量减少,此前数月的高剂量化疗与清除自动吸附剂细胞产品",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,每天只有一个群组康复者Armodafinil P.O.每天,在二级试验中,所有病人都得到相同的PDR001剂量,但得到不同的MCS110剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "第一次试验的结果显示,在手术前7天和乳腺癌手术后14天每天20毫克的tamoxifen 20 mgpo将肿瘤中的Ki67表现平均减少40%。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "CAPECITABINE每天通过口服管理,第一个21天周期初级审判第2组第2组的每个病人都接受口服管理。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "与初级试验不同,必须诊断出以下基因之一的病人有突变:PTEN、BRAF、KRAS、NRAS、PI3KCA、ErbB1、ErbB2、MET、RET、C-KIT、GNAQ或GNA11, 将纳入二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "初级审判第2组比二级审判第1组记录了更多的动脉、心肌梗塞和腹部疼痛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "在初级审判中,至少记录了1起胃肠不利事件和2起或2起以上精神病事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验中使用的Lenalidomide剂量高于干预1中使用的Lapatinib二次试验剂量,初级试验干预持续的时间更长。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "初级审判中记录的所有Aes 发生在第1组病人身上",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "初级审判的病人不遭受与二级审判的病人相同的不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "在初级试验中,每天只有一个组群康复者Armodafinil P.O.,在二级试验中,所有病人都得到100毫克的PDR001剂量和1毫克/千克的MCS110剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "与初级审判相比,在二级审判中观察到的不利事件更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "第二次试验和初级试验使用同样的结果衡量;在完成化疗后,乳腺癌中患有pCR的病人比例,被定义为没有侵入性肿瘤在外科手术中仍留在乳房的证据。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "我们不能比较初级审判和二级审判中的不利事件,因为这些事件似乎没有记录在初级审判中。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "无论是二级审判还是初级审判都没有衡量 \" 肿瘤中基67表达式变化 \" 。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13%的PPR+初级乳腺癌初级试验参与者得到HER2目标PET/CT治疗。 89Zr-trastuzumab开发了HER2+代谢",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级审判第2组患者患中肺炎的频率大大低于二级审判第1组患者,后者的Empegfilgrastim剂量要低得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "功能障碍患者被排除在初级审判之外,但超能力障碍患者可能有资格接受二级审判和初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "第一次审判干预以口头方式作出,而第二次审判干预则完全通过针管或针管插入静脉进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非裔美国人的病人可以参加初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "被诊断患有肿瘤性脑膜炎的病人有资格接受初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ]
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "初级试验第1组中的大多数病人,不论癌症类型如何,在干预后都及时进行了筛查。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "他们的口头发言由初级审判和二级审判管理。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "初级初审和关于不同干预措施的MTD二审报告,二级审判病人的MM-111的MMT-111的MMT为每天15毫克",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "初级试验中的乳腺癌和骨癌/脊髓癌病人接受同样的治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验组第1组比第2组病人接受多克索氏剂的Eribulin剂量高",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "据记录,在二审期间经历胸痛的病人比在初审期间经历这种痛苦的病人多得多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "两个主要试验组群均获得战前的德士马西松",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "在初级审判中记录的所有不利事件都与肌肉骨骼系统有关,而二级审判的情况并非如此。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "初级审判的第1组和第2组人以同样频率获得CUDC-101的同样剂量,唯一的不同是第1组人也每周一次重考PD-0332991。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "与初级审判相比,二审中比起二审中比起二审中更多的是二审中二审和腹泻案件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            2,
            5
        ]
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "初级审判的两组人在整个审判期间都以同样频率获得多克萨斯、多克索罗比辛和西氯磷酸盐的同样剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级试验的Cohorts 1和2采用同样节奏的呼吸教育CD,然而,2组人每天两次练习,每周进行抗乳粉化疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足了初级审判的所有排斥和包容标准,最终的包容决定也将由其直系亲属的患者做出。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "患有严重失眠症的病人被排除在初级和二级审判之外",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "与Bevacizumab + Capecitabine组相比,初级审判中的Bevacizumab组比Bevacizumab + Capecitabine组产生更好的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "初级审判中ER-正阳性卢米纳尔B组的参与者比 \" 三负集团 \" 的参与者多11%,表明增长因数签名比增长因数签名减少",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "32岁的病人对第三阶段乳腺癌进行经生理学核实的诊断、1807/L的绝对肺癌计数、110 034/L的血红蛋白计数、90克/升的血红蛋白水平以及超过8个月的预期寿命,均有资格接受初级和二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "第1组或第2组第一或第二组主要试验病人中,没有一个显示表明40种经评估的基因的可辨别模式。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "具有肺栓塞史的病人不能参加第二次试验,而目前已植入乳房的病人不能参加第一次试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            13,
            20
        ],
        "Secondary_evidence_index": [
            12
        ]
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "过去两个月内患有肺栓塞症的病人被排除在初级审判之外,但根据调查员的决定,可能有资格接受二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "第二次审判对所有参与者的包容/排斥标准相同,而第一次审判则有两套包容标准,一套是18-50岁年龄组,另一套是50岁以上年龄组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "第二次审判的第2组比初级审判的第2组产生更好的结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "一审结果显示,AA干预的总体应对率高于安慰剂手臂,此外,在二审中,Denosumab组比Zoledronic酸组有更好的时间进行第一次研究SRE。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "初级试验采用专题干预,二级试验测试吸入干预。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "共有2名初级审判的病人患有剂量限制毒性的发病率,两人都是第2组患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "初级审判和二级审判记录了同一批人遭遇的不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "初级审判中的干预1由IV管理,二级审判中的所有干预药物都可以口头管理。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "上个月接受器官移植手术的病人,将被排除在初级审判之外,但可能有资格接受二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "在整个研究期间,每天向接受初级审判的每个病人口服Sunitinib。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "与快速、浅度呼吸组的病人相比, \" 快速呼吸 \" 干预组的平均患病率要高于 \" 快速、浅度呼吸组 \" 的病人。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "18或19岁的妇女有资格接受二级审判,但需要等待1-2年才能有资格接受初级审判",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "少于一半的初级审判参与者在通过抽除自动吸液细胞产品进行高剂量化疗后减少了循环肿瘤细胞",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初试病人在整个学习期间将获得更高剂量的阿尔法利皮酸,而第二审第1组病人在整个学习期间将获得同样的Necitumumab剂量的Necitumab。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级审判第1组和第2组之间的差别是,第1组每天服用25毫克至37.5毫克血清,第1组每天服用25毫克至37.5毫克血清,而第2组则服用10毫克/千克白鲸b",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初级审判候选人都必须有一个HHER2阳性肿瘤,由IHC 3+确认,同样需要大量援助和经常医疗护理。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2
        ]
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "初级审判的结果显示,A型武器干预提供了最佳的总体回应率,此外,在二级审判中,Denosumab组比Zoledronic酸组更难完成第一次研究SRE。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "NUT中线癌或耐控前列腺癌的病人,由荧光异地混合化确定,或发炎性乳腺癌,均有资格接受初级和二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级试验参与者接受整个乳腺辐射治疗,二级试验的两组人都得到500毫克的肉毒杆菌,将采用BID的平板形式。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "二级和初级二审的几个病人患有Tumour透析综合症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "与二级审判相比,初级审判中的Broncophopneumonia和一般身体健康恶化案件更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "初级审判第1组的参与者没有一个被发现有损伤,第二审判第1组的参与者95%以上患有辐射性皮炎和高血压。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "初级审判的所有参与者,尤其是Ovarian 功能制止小组的参与者,认知功能恶化。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "在初级审判中至少有一名病人接受了GTx-024 1mg的GTx-024治疗,",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "在初级审判中接受安慰剂干预的病人患迷魂症的可能性是服用迷魂药的病人的两倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "吸烟者被排除在初级审判之外,但如果每天饮酒少于5杯酒精饮料,则有资格参加二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "第二次试验使用疼痛作为物理治疗有效性的衡量尺度,而第一次试验研究则使用Sulforaphane补充剂对尿液中伊瑟皮亚氰酸盐浓度的影响。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "初级试验组第1组的大多数病人都遭受了不利事件,第2组的情况正好相反。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "在初审和二审中至少有1个感染病例",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            11
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "在初审和二审的病人组群中,没有观察到任何先天障碍或Pancetopenia事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "与初审时的病人相比,二审病人患贫血、肺炎和眩晕的频率更高,但初审时记录的FEBRILE感染病例更多。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "第一次试验的干预一和两次试验的区别是,内网1使用pIHGC,而干预2使用stantdard GP。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "即使患者满足了初级审判的所有排除和包容标准,也将由负责审判的卫生专业人员作出最后的包容决定。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96名来自Ketolololac30毫克的初级审判组的96名参与者经历了无重复的存活,而NaCl 0.9% 3毫升组的67名参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "32岁的病人对第三阶段乳腺癌进行经生理学核实的诊断,1807/L的绝对肺癌计数,79000/L的血红蛋白计数,90克/升的血红蛋白水平,以及超过8个月的预期寿命,均有资格接受初级和二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            10,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            0,
            2,
            3,
            4,
            7,
            8,
            9
        ]
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "初级初审行政主管以次语言进行干预,二级初审行政主管以口头方式进行干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "初级审判第1组记录了几起贫血和二月肺炎病例,但Pancytumponia案件为0起。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级审判的干预1和干预2之间的唯一区别是,与第二组相比,第1组每月注射的Durva疫苗比第1组少0.7毫克,比第1组少0.7毫克。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "阿尔茨海默氏病患者没有资格接受初审",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4
        ]
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "Palitaxel Plus Bevacizumab Paclitaxel Plus Bevacizumab+ Gemcitabine 组的初级试验中,ORR比Palitaxel Plus Bevicizumab组的OR要好,参加人数更多",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求病人每个月获得120毫克的阴性阴性膜注射,第二次试验不需要注射,而是使用淋巴素描。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "二级审判和初级审判之间唯一共享的包容/排斥标准是提供书面知情同意的能力。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "LBH589和Capecitabine一起初审的LBH589比LBH589和Lapatinib的结果更差。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "初级审判中发生了一起精神不良事件,影响不到10%的病人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "第二次审判中最常见的不利事件是贫血,在初级审判中没有记录到AEs。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "据记录,在第二次审判中经历Aes的病人比在初级审判中经历Aes的病人多得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "任何日本国民都可以参加初级审判或二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38,
            39,
            40,
            41,
            42,
            43,
            44,
            45,
            46,
            47,
            48,
            49,
            50,
            51,
            52,
            53,
            54,
            55,
            56,
            57,
            58,
            59,
            60,
            61,
            62,
            63,
            64,
            65,
            66,
            67
        ]
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "厌食病人有资格接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "在初级审判中记录的唯一急性呼吸道炎是口炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "在初级试验中,阿塞克人比较常见,肺炎肺炎在二级试验中更为常见。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "过去三年内诊断患有扩散性近血球肺病的成人病人将被排除在初级试验之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "在不列颠哥伦比亚省第四阶段接受过乳房切除术的妇女仍然有资格接受二级审判或初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级审判和二级审判的候选人必须符合基线业绩状况,每个审判都采用不同的业绩状况评分制度。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试验参与者经7种不同种类的药物后必须接受外科手术,而二级试验参与者只接受两种不同的药物,无需接受任何外科手术。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级审判的两次干预都包括暴风淋巴",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "新诊断的当地高乳癌妇女,经确认为ER+,认为乳房切除符合初级和二级试验的条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "在初级审判中,不到5%的病人患有艾斯症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "被诊断患有白细胞癌的病人在初试和二审时可能有资格参加所有研究组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "作为干预的一部分,没有一个初级审判候选人必须经常参加常规演习。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验是测试不同辐射疗法对研究组的影响,而二级试验是测试研究组不同剂量的相同治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "在初级审判中观察到0起不利事件,在二级审判中,没有一起不利事件影响到30%以上的病人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "第二次审判的干预持续了15周,比初审中详细说明的干预持续了15周。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "只有初级审判第1组才能将教育DVD视作为干预的一部分。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "乳腺癌中经生理学或细胞学确认的经转移和/或高级固态肿瘤患者有资格参加初级试验第一阶段和二级试验的所有组群。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31
        ],
        "Secondary_evidence_index": [
            2,
            3
        ]
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "在一审和二审的病人组群中,共有3例闪烁。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "通过临床检查和回声摄影测量半径为3毫米的初级肿瘤患者有资格接受初级和二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "关于各种干预措施的初级审判和二级审判报告",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "患肥胖症的病人有资格接受初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初级试验病人得到的辐射治疗剂量高于二级试验参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有一个测试组和一个安慰剂组,二级试验有两个测试组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须抵制AI疗法和mirtazapine才能参加初级审判,但没有必要列入二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "初级审判的安慰剂干预和Allo-MSC干预以同样的剂量通过心肺移植注射进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "第二次审判对所有参与者的包容/排斥标准相同,而第一次审判对不同的研究组有两套包容标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ]
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "初级审判第2组没有死亡或住院治疗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "两次乳房肿瘤都可测量的病人被排除在初级试验之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1
        ]
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "每个接受初级试验的病人都必须每天在放射治疗期间吞下一粒Vorinostat胶囊。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童没有资格接受初级审判,但他们没有明确被排除在二级审判之外",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "第一次试验的干预一和两次试验的区别在于,干涉1使用比干预2使用高剂量的放射性Tc99M硫磺共聚物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "与二级审判相比,初级审判记录的全部不利事件和不利事件类型较少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "初级审判第1组和第2组之间的差别是,第1组每天服用25毫克sunitinib,而第2组则服用90毫克/m2帕利塔克赛。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "过去6个月内,患者如果想参加初级试验,就不能有腹腔瘘、胃肠道穿孔、心肌梗塞、中风、短暂缺血性袭击、腹腔内出血或严重精神紊乱的历史。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            13,
            11,
            19
        ]
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "二级试验研究组的候选人每周接受次针注射,而初级试验参与者则不接受任何注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选人在能够参加初级审判之前必须接受乳房X线照相检查,而二级审判不需要这种检查。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的病人,如果有乳癌呈阴性ER阴性,可有资格参加初级审判的两个阶段。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12,
            14,
            15
        ]
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "患有幽闭恐惧症和骨质疏松症或没有资格接受初级或二级审判的妇女。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3
        ],
        "Secondary_evidence_index": [
            2,
            9
        ]
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "在初级审判第1组第1组中记录的所有艾斯人都与心理健康有关。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8,
            9,
            10,
            11
        ]
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "对非小细胞肺肺癌或小细胞肺癌进行肿瘤学/细胞学确诊诊断的病人有资格接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32
        ]
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "第一审判组第1组接受战前的德西米哈松治疗,第二组接受德西米哈松治疗,在行动2小时后接受。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "育有生育潜力的妇女和性活跃的育龄男子有资格接受初级审判,但她们必须承诺在整个学习期间禁欲。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "初级试验有一个测试组和一个安慰剂组,二级试验有一个测试组和一个控制组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "在初级审判和二级审判的病人组群中,最经常发生的不利事件是Syncope,在25.0%的初级审判病人中发生了这种情况。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "没有需要满足的精神心理健康、体重、年龄、Karnofsky/ECOG得分或以前治疗条件才能有资格接受初级审判的条件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在一审和二审期间没有心脏病或精神疾病记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "苏拉敏和帕利塔克斯对所有在初审中的病人进行治疗,二级试验干预科没有说明要服用什么药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "初级试验第1组和第2组病人接受同样的剂量的辐射治疗,所有病人都接受SPECT扫描。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "初级审判的参与者没有肝功能条件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "在初级审判中记录到的心肌梗塞、心肌梗塞和腹部疼痛比在二级审判中记录得更多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "初级审判干预科没有概述治疗周期或对治疗的任何描述",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "在一审或二审中,没有发生意外死亡或住院的情况,记录的唯一急性呼吸道感染病例是3例淋巴瘤。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "初级审判第1组的参与者使用肺炎球菌疫苗,第2组的参与者使用流感疫苗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "希波白血病患者被排除在初级审判之外,但可能有资格接受二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "帕利塔克斯只用于初级审判的第1组干预,而第2组则用于管理支流",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "参加初级试验的参与者在整个学习期间接受4种不同的药物,最高剂量为100毫克/平方米。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "无论是初级审判组别还是初级审判组别,在干预措施中都不接受任何咨询、风险评估或反恐委。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级试验在其两个阶段采用单独的包容和排斥标准,而二级试验则对健康病人和癌症病人采用单独的标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在整个初级审判和二级审判期间,在不利事件中记录了10多人死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "直径为0.2-0.8厘米的乳腺癌直径为0.2-0.8厘米的病人,经确认具有人力资源阳性和她2阴性状态的病人,有资格接受初级和二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "在二级审判中,比在初级审判中多的是Bilazic colic和Clostridium difficile colitis案件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            6
        ]
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "初级试验两组的42名以上病人在手术大约7个月后在乳房和轴心淋巴结结中经历了病理学全面反应",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "所有符合二级审判条件的病人也有资格接受初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "在一审或二审中,没有发生意外死亡或住院的情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "初级审判的Neratinib小组的iDFS比率低于安慰剂小组",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "初级审判的第1和第2组采用同样节奏的呼吸教育CD,但第2组每天两次练习。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "平均而言,初级审判的两个组群的认知功能都恶化了,但并非所有患者都是这种情况。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "50%以上的初级初审第1组病人在接受Apripitant、Dexixmethasone、Cytoxan和Kytril治疗后急性呕吐。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "第二次审判的干预持续时间比初审中详细说明的干预时间长3倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "在一审和二审中,有0例二月肺炎或霍乱病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "无法测量代谢症患者或癌症未蔓延至身体其他部位的患者没有资格接受初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "只有2名初级初审的病人没有再生的存活能力",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "初级审判中发生了几起精神病不良事件,包括饮食紊乱和精神分裂症。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "NUT中线癌患者由荧光体确定,现场杂交或发炎性乳腺癌既有资格接受初级试验,也有资格接受二级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "初级审判和二级审判的候选人必须达到基线业绩状况;初级审判的基线是Karnofsky分数 >70;二级审判的基线是Karnofsky分数 >55。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            8
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "患有对Tstruzumab有严重厌食反应的病人不能参加初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17
        ]
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "在初级审判或二级审判中,没有任何患者在3个不同的申请庇护者之下遭受过痛苦。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "第二次审判或初级审判都没有使用 \" 具有治疗作用的Aes的参与者人数 \" 作为其学习成果的衡量标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "在初级审判中没有记录有Aes的病人,而在二级审判中,每个病人至少遭受一次不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "初级试验在干预1中使用的Lapatinib剂量高于二级试验使用Lapatinib剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "另一方面,第二次试验则报告经历 \" 目标反应 \" 的病人人数。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "在初级审判中记录到的口腔、血压感染和血栓塞病例比在二级审判中记录到的多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验不测试任何基于药物的治疗方法,而二级试验测试两种不同的药物。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "在初级审判中,5名5名病人遭受了3次或3次以上的不利事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "所有接受初级试验的病人每3周至少得到20毫克MCS110,每另外3周得到130毫克PDR001。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "原位恶性肺癌和无控制的高血压患者有资格接受第二次审判,但被排除在初级审判之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            12
        ]
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "初级审判第1组第1组使用0.035毫克ALT-801ALT-8小于第2组",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "初级审判组没有在干预措施中发现任何药物、放射疗法或CBT。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ]
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "与第二审判候选人第1组相比,初级审判候选人每周获得的MM-121和Paclitaxel少于第二审判候选人第1组。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "Asthenia共有3个病例和5个Pyrexia案件,记录在初审和二级审判的病人组群中",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "初级试验干预部分剂量没有说明管理方法、剂量或周期。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "几个在初级试验中处于正常维生素D水平的病人表现出了40种经评估基因的可辨别模式。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "曾经接受过乳房切除术的妇女仍然有资格接受二级审判或初级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "与初级审判相比,第二次审判记录比初级审判多11个Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "可计量的双边乳腺癌患者有资格接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1
        ]
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "初级审判和二级审判的Aes记录了几起肿胀、体温过低和混乱的案件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "育龄妇女和性活跃育龄男子有资格接受初级审判,但必须满足一些额外要求。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            20,
            21,
            22,
            23
        ]
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "初级审判的参与者在预期寿命、怀孕或年龄方面没有任何条件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36%的初级受试病人的血液树脂增加。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "在二审的病人中观察到的唯一类型的Aes是Eyelid oedema和Chest疼痛,在一审中没有Aes记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "初级审判在两个阶段采用单独的包容和排除标准,而二级审判对所有参与者采用同样的标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36,
            37,
            38
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "参加初级试验中20毫克/千克的dalotuzumab 20 mg/kg组的参加人数比参加三负组的参加人数多49.2%",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "初级试验参与者接受整个乳腺辐射治疗,二级试验的两个组别都接受肌肉内注射,如口服药物一样。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "初级审判中不到10名病人患有艾斯病",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "初级审判的参与者多于二级审判的参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别不是获得初级审判或二级审判资格的决定因素",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "初级审判和二级审判没有记录参与者的任何不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "接受初级试验的病人中,25%患有增加的胸膜破灭和快速疾病发展",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "两种初级试验干预措施均不使用帕利塔克斯",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "另一方面,第二次试验则报告经历 \" 目标反应 \" 的病人百分比。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级审判中的所有感染和发烧病例都针对第1组患者。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "初级审判的病人需要注射几针",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta用于二级审判的两个组群,但在初级审判中根本不适用。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "初级审判参与者比二级审判参与者常见两倍于二级审判参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "对初级审判的干预包括一种单一药物ZD1839,而在二级审判中,干预至少需要三种不同的药物,包括Zoledronic酸、Samairo-153和egfilgrastim。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "诊断出肿瘤呈阳性的病人在CPND1增殖、CDK4/6突变、CCND2增殖中呈阳性反应的病人被排除在初级审判之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "在初级审判中,安慰剂干预和Memantine干预以同一频率进行,时间相同。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "所有在初级审判中接受GTx-024 1毫克GTx-024治疗的病人在4个月期间获得利安身体",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "第二次审判或初级审判的用法变化都不足以衡量他们的学习成果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "非裔美国人的病人可以参加初级审判,但他们在研究期间必须居住在德克萨斯州。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "初级审判和二级审判都使用pCR作为结果衡量标准,初级审判的两个组别之间结果略有不同,而在二级审判中,Arm 2的结果比第1股差,因为第2股病人中经历pCR的百分比较高。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "在初级审判的不利事件中比在二级审判中更普遍地看到经常恶性肿瘤、 Graft-vers-host疾病、感染、改变精神状态和Diffuse alveolar出血。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "初级审判第1组的参与者中,没有一人被发现有损伤,第二审判第1组90%以上的参与者患有辐射性皮炎和高血压。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "在初级审判和二级审判中,有超过1%的参与者发生了0起不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初级试验结果报告疼痛强度变化,二级试验衡量腰脊骨骨矿密度从基线变化为9个月,从基线变化为9个月。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级审判和二级审判在干预措施中使用的药物、剂量或管理频率不同,但它们都使用静脉注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "在初级审判中,肝中毒病例数量是肝中毒病例的3倍,因为有高血压和脊椎切除术病例。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3,
            4,
            5
        ]
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "诊断出第四阶段感染性乳腺癌(雌激素和/或蛋白酮受体呈阳性)并正在考虑接受AI疗法的病人有资格接受初级试验。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "在初级试验期间,两次干预都使用了激光辅助荧光血管成形术和横向射线切开术。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "在初级审判中,没有两名病人遭受同样的不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "初级审判中的白血病组比白血病组和开普西塔比因组的发病率高。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "初级审判和二级审判中发生了0起不利事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "初级审判记录的大多数不利事件与血液和骨髓有关,二级审判的情况并非如此。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13%的初级试验参与者接受HHER2初级乳腺癌治疗的HER2-目标PET/CT。 89Zr-trastrstuzumab研制出可想象的HER2+代谢",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "第一次审判的安慰剂干预和Allo-MSC干预用一次性心肺注射在同一剂量下进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "初级试验参与者在第1天、第8天和第15天获得与sargramostim(GM-CSF)混合的HHER2-NE Peptide疫苗(GM-CSF)ID",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "患有新诊断的ER-ER-呈阳性、HER2-阴性乳腺癌的20岁女性病人,可有资格接受二审和初试",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "初级审判没有报告LBH589和Lapatinib群组的任何结果。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级审判干预1中的Zoledronic酸剂量是二级审判干预1中使用的Denosumab剂量的12倍。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两个主要试验研究组将同时接受18FF-FDG和18FF-FPPRGD2号正对射线断层摄影/计算断层成像程序。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "儿童和青少年没有资格接受初级审判,因为他们不符合身高要求,但是他们没有被明确排除在二级审判之外",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33
        ]
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "在初级审判中观察到零起不利事件,在二级审判中,除皮肤感染外,没有一起不利事件影响到30%以上的病人。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "参与者必须抵制AI疗法才能参加初级审判,但没有必要列入二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "18岁以上的女性癌症患者可以参加初级审判,而不论其种族、族裔或癌症类型如何,但是在二级审判中,她们必须患BRCA+乳腺癌。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "二级审判和初级审判均使用目标认知功能分数,以科格州衡量为衡量单位。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级审判第2组比第1组多7人",
        "Label": "Entailment",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "Kras或BRAF突变后, 被确诊患有代谢性直肠癌的病人在初试时的可用位置有限。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            3
        ]
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "与初级审判相比,二级审判记录的病人群体中不良事件总数略高于初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "初级审判中所有AE型所有AE型都受到影响的病人不到10%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "没有记录初级审判或二级审判的Aes记录。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "只有4种不同类型的不利事件影响到初级审判中的病人,所有这些病人都属于第2组",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29
        ]
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "性别不是初审资格的决定因素,只有女性病人才有资格接受二审",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "没有接受热热疗的初级试验病人的症状比接受热疗的病人的症状更严重。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "二级审判和初级审判之间存在0项共同包容/排斥标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "Paclitaxel Plus Bevacizumab Paclitaxel Plus Bevacizumab Plus Gemcitabine小组的初级审判阶段,其有机权利优于Paclitaxel Plus Bevacizumab小组",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "在初级审判中,患者的淋巴肿变化优于等待治疗名单上的患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "在初审和二级审判的病人组群中,最经常发生的不利事件是Syncope",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "病人的国籍、族裔、体重或性别不影响其参加初级或二级审判的资格。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30,
            31,
            32,
            33,
            34,
            35,
            36
        ]
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "初级审判是使用荷尔蒙干预,二级审判是测试针刺干预。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初试和二审对患者的不同特征进行结果评估。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参加初级审判的病人每天两次全月获得口服药物治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "与NaCl 0.9% 3毫升组相比,初级试验中Ketolololac 30毫克组的存活率为-6.4%",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ]
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13名初级审判参与者接受了Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-KLH同质疫苗的治疗",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "目前参加第二次审判的任何病人也有资格参加初级审判,因为他们具有相同的包容标准。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "在初级审判中,安慰剂和创伤和创伤性紧张症的干预以同样的方式进行,但在不同的日子进行。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "第二次试验使用肌肉增益作为物理治疗有效性的衡量尺度,而第一次试验研究则是Sulforaphane补充物对尿液中异硫氰酸盐浓度的影响。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "初试和二试不试验同一种药物",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "主要审判干预科需要外科和成像程序。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "具有有历史记载的转移性SCBC病人不在初级审判之列。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "二级审判和初级审判报告由一个病人组群产生。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10
        ]
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "过去3年内诊断患有IDL/DPLD的成人病人,其预期寿命为6个月,有资格接受初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            19,
            22
        ]
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18岁的人被排除在二级审判之外,但初级审判没有规定参与的年龄范围。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级审判的两个组群都得到同样的Abraxane剂量。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "初级审判中的所有感染和感染病例都针对第1组患者。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "第二次审判或第一次审判均不使用cm、参与人数或时间单位作为衡量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "在初级试验中,没有接受丙烷注入的病人的症状比没有接受丙烷注入的病人的症状更严重。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "初级审判第1组记录了1起贫血和二月肺炎病例,但没有记录到Pancetopenia案件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "初级试验第1组和第2组病人接受同样的辐射治疗剂量,但第1组病人的干预持续两周以上。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "参加初级审判的任何人都没有受到UTI的审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ]
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级审判和二级审判同时管理环磷酰胺、帕利塔克斯勒和病人组群的pegfilgrastim。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "初级审判的 Cohort 1 与第2组得到的Cetuximab剂量与第2组相同,但又增加了一项合作护理干预措施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "18岁以上的女性癌症患者可以参加初级审判,而不论其种族或民族血统或癌症类型如何,但在二级审判中,她们必须得HER2/NEU+乳腺癌。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "通过临床检查和回声摄影测量直径为33毫米的初级肿瘤患者有资格接受初级和二级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "第二次试验和第一次试验的结果采用不同的计量单位,以衡量同一结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            9
        ]
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "二级审判和初级审判使用相同的计量单位报告其结果。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "新诊断为PR-呈阳性、HER2呈阳性乳腺癌的年轻女孩可有资格接受二审和初审。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "初级审判干预是按专题进行,而二级审判干预则完全通过插入血管的针管或针管进行。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "初级审判的两组人都获得相同剂量的Abraxane和Carboplatin的Abraxane和Carboplatin。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "初试病人的平均寿命超过2年,但两组患者中至少有一名在2年内死亡。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "直径100毫米的TNBC肿瘤患者有资格接受初级和二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ]
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "初级审判只记录其患者组群的单一不利事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "患肥胖症的病人有资格接受初级和二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "所有初级审判参与者获得的ALT-801剂量高于二级审判参与者",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "接受二审和初级审判的大多数病人没有遭受任何不利事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "在初级审判中记录到的口腔、癫痫和血清栓塞病例多于在二级审判中记录到的口腔、癫痫和血栓塞病例。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级审判的第一组被注射了氟化硅酸盐,第二组被注射了标准剂量的氯仿。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "初级审判的干预1和干预2的唯一区别是,与2组相比,Durva的双周四注射中第1组恢复剂为0.7毫克/千克,比第2组少0.7毫克/千克。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "初级试验参与者经7种以上不同种类的药物注射后,通过亚皮注射进行7种不同的药物,并必须接受手术,而二级试验参与者只接受两种不同的药物和若干种不同的成像扫描",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "主要试验干预部分没有概述治疗周期或辐照剂量说明。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "平均2年以上的初级试验病人平均存活2年以上,每个组群有50多名病人存活24个月以上",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "初试97%的病人没有经历任何不良事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "二级审判和初级审判至少有一项包容标准。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "在初级审判组中的任何一个组中,都有0个超高血压、脱水和Dyspnea案件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "初级试验组群的内特人接受任何侵入性外科手术或内拉蒂尼b",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "任何被诊断患有纤维瘤、血清综合症或贫血症的癌症患者,都无资格接受初级和二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            8,
            9
        ],
        "Secondary_evidence_index": [
            8
        ]
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "在初级审判的不利事件中,经常发生的恶性肿瘤、 Graft-vers-host疾病、贫血、心脏病和Diffuse alveolar出血比在二级审判更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24
        ]
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "在二级审判的第2组中记录了1个Singles案件,但在第1组的二级审判和初级审判中没有1个案件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "初级审判的两组人都记录了0个Aes",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "在初级审判阶段的2组病人中,25%的2组患者患有增加的胸膜破损",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            7
        ]
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "病人的国籍、族裔、精神状况或性别不影响其参加初级或二级审判的资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            12
        ],
        "Secondary_evidence_index": [
            34
        ]
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "二级审判候选人必须完全残疾才能参加,而初级审判不须接受这种资格。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "在初级审判第1组中遭受不利事件的病人比初级审判第2组中遭受不利事件的病人多4人",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "第二次审判和初级审判的结果衡量完全不相干,但同样的干预措施",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "第二次审判或初级审判都没有衡量其学习参与者中接受临床福利(使用(RECIST)标准)的百分比",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "二级审判第2组的病人比初级审判第2组的病人多得多。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            17,
            18,
            19,
            20
        ],
        "Secondary_evidence_index": [
            11,
            12,
            13,
            14,
            7,
            16
        ]
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "在初级试验第2组第2组患者中,50%以上在接受过Apripitant、Dexamethasone、Cytoxan和Kytril治疗后急性呕吐。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "初级审判参与者得到双倍于二级审判参与者得到双倍的unitinib。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "参加初级试验的病人全月每天两次得到100毫克/平方米口服大腹膜炎,口服100毫克/平方米。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4
        ]
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "初级审判和二级审判评估有重大利害不良事件参与者的百分比",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "在初级审判组中的任何一个组中,均有0个超高血压、爱德马和Dyspnea案件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21
        ]
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "在初试期间,病人的心肌梗塞更常见,在二审期间,科内尔的存款更常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "初级试验报告研究分析的参与者总数,但没有报告每个组群的参与者人数。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            11,
            21
        ]
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "初级试验没有测试任何药物治疗方法,而二级试验测试一种药物治疗的不同剂量",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "乳腺癌患者呈雌激素阴性、原孕酮阴性、HER2-肿瘤,所有初级试验组都有资格接受",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "参加初级审判的候选人必须患有乳腺癌,并需要激素治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "初步试验结果报告的主要试验结果报告为1至7级的 \" 延迟纳usea之严重性 \",第二次试验衡量了腰椎骨矿密度从基线变化为9个月的情况。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "初级试验的AZD0530175毫克组的原生肿瘤直径的减幅大于Zoledronic酸4毫克组。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "患有TX NX MX、T0 NX M0或T1 N1 N1 M1肿瘤的病人有资格接受初级试验",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            2,
            3,
            4
        ]
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "参加初级审判的候选人必须患有结肠癌,对以前的荷尔蒙治疗没有反应。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            1,
            2
        ]
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "初级审判评分组和二级审判组和二级审判组的两次审判组都没有获得不同的剂量",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "候选人必须先接受乳房X光检查,然后才能参加初级审判,而对于二审病人,必须先进行CT扫描和血液检查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ]
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "与第二次审判参与者相比,所有初级审判参与者获得的药物剂量低于第二次审判参与者",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "一般症状是初级试验中记录的最常见常见的AE症状。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Arimidex用于初级审判的两个组群,但在二级审判中根本不适用。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "参加初级试验的学员在整个学习期间接受4种不同的药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "在初级审判中,至少有一个记录在案的胃肠道不利事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "任何在入院前一个月接受过抗塑胶化疗、甲状腺素、雌激素或蛋白质治疗的病人,均被排除在初级试验之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "初级审判和二级审判在干预措施中使用的药物、剂量或管理频率不同,但它们使用静脉注射和吸附机。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "初级审判第1组第1组的剂量低于第2组ALT-801ALT-801ALT的剂量的一半。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "初级审判合组1没有报告任何Aes案",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "禁止初级审判候选人接受基于军法的治疗,但他们可能仍然有资格接受二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            31
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "具有经精神学确认的第四阶段乳腺癌患者,如果是ER阳性、PR阳性或HER2负性,则有资格接受二审和初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4
        ]
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "同一比例的病人在初级审判的两组人中都遭受不利事件的伤害",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "在初级审判中拥有最长的PFS的病人存活了3.5个月,没有疾病发展或死亡",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "初级审判中记录的个别不利事件类型无一影响超过患者群的四分之一",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "初级审判是评估遭受与不利事件有关的治疗的病人人数,而二级审判则是衡量病人在小时中的平均睡眠时间。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "初级审判第1组患者遭受不利事件的人数多于第2组患者的人数。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            13,
            14
        ]
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "患肥胖症和怀孕的病人有资格接受初级和二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "初级审判的大多数病人在第24周前都得到完整答复。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "初级审判中的两种干预措施都包括同剂量的Paraplatin",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "患有严重失眠和精神分裂症的病人不参加初级和二级审判",
        "Label": "Entailment",
        "Primary_evidence_index": [
            25
        ],
        "Secondary_evidence_index": [
            6
        ]
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级审判和二级审判的干预措施都要求病人每周接受4-二甲基-4-一氯-1-一氯-1-一氯二氟丙烯的循环治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "在初级试验中接受Lapatinib 1000 mg + Nab-Paclitaxel治疗的1/2以上的病人得到确认的完整反应(CR)。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "在一审和二审期间,没有记录到心脏或心肺炎记录,但观察到了其他几类心肺炎。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "初级试验干预包括使用Yttrium-90玻璃微镜和TheraSphers进行放射性消化,另一方面,二级试验干预包括560毫克的ibrutinib和10毫克/千克的MEDI4736,每月两次。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "任何目前吸烟的病人不能参加初级或二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27,
            28,
            29,
            30
        ],
        "Secondary_evidence_index": [
            5
        ]
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "初级试验是测试不同凝胶对研究组的影响,而二级试验是测试研究组不同剂量的相同治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "初级审判组或二级审判组没有一组人获得肠内涂涂片片片",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "任何在入学前的最后2年中接受过抗塑胶化疗、甲状腺素、雌激素或蛋白质治疗的病人,均被排除在初级试验之外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "初试期间的乳腺癌患者每天接受1 000立方米的塔拉索帕里卜治疗,而初试期间的Ovarian/脊髓癌患者每天只得到25毫克的塔拉索帕里卜治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "初级审判第1组中只有61名子宫颈癌患者在干预前及时接受了筛查。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "腹泻在初级审判参与者中比在二级审判参与者中更为常见",
        "Label": "Entailment",
        "Primary_evidence_index": [
            5
        ],
        "Secondary_evidence_index": [
            6,
            21
        ]
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级审判第1组第1组的100.0%遭受了某种不利事件",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "参加二审的Sunitinib-nave参加二审的Sunitinib-nave人获得sunitinib的两倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "维生素D缺乏症患者被排除在初级审判之外,但可能有资格参加二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "初级审判和二级审判的干预措施包括完全不同的药物治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "初级审判候选人的每周获得的MM-121和Paclitaxel比二级审判候选人第1组获得的每周最低MM-121和Paclitaxel要少,但雌激素和多氧酸盐的剂量要高一些。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "任何患甲状腺素、三甲基甲状腺素/磺酰胺氧甲醇、甲状腺素、甲状腺素毒素或蛋白氧的有文件记载的过敏性病人,均无资格接受二审和初审。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            24
        ],
        "Secondary_evidence_index": [
            9
        ]
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "与二审相比,在初级审判的不利事件部分,可疑的严重不利反应更为常见。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "初级审判第2组没有死亡或住院治疗,只有一例人工纤维结裂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            5,
            6,
            7,
            8,
            9
        ]
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "初级审判的第1组被注射氟化硅酸盐,第1组被注射四氯杀螨剂。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "初试和二试的所有病人都接受苏拉敏和帕利塔克斯的治疗。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "对初级审判参与者来说,maculo-papular Rash是一种常见的不利事件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "两个主要试验研究组将接受同样的18FF-FDG和18FF-FPPRGD2 红外线排放断层摄影/计算断层成像程序,但第1组将接受18F-FPPRGD2略高剂量的18F-FPPRGD2除外。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "第二次审判和第一次审判的结果衡量完全不相干。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "在初级审判中,第1组病人中发生了几起在初级审判中记录的若干起Aes案",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25
        ]
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "初级试验要求病人每月必须注射120毫克的二硝基苯甲胺,二级试验也需要注射,放射性Tc99M硫合物0.4至1.0毫Ci的放射性Tc99M硫合物需要注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "初级试验类别2中的0.5微克/千克脱氧甲胺(5毫升),二级试验组群的病人得不到任何Dexmetetomidine。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "二级试验研究组的候选人每周得到3次次针注射,而初级试验参与者在研究开始时只得到一次注射。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验每6周内每2周用150毫克的口服预gabalin来治疗其一个病人组群,二级试验治疗其糖尿病和HD-MTX病人。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "初审时共有两名病人患有剂量限制毒性,每组1人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ]
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "在初步试验结果中,第12周与第24周相比,第12周与第24周患稳定疾病的患者人数更多,但第12周或第24周有0名患者得到全面回应",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "初级审判和二级审判记录了病人组群中相同数量的不利事件总数。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "具有有历史记载的转移性或不可解剖的SCBC病人不在初级审判之列,除非这些病人对ER或PR或两者都具有阳性。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ]
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "初级审判中的Cetuximab与第2组受到的Cetuximab剂量相同,但比第2组少8毫克/千克MMM-121。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "在整个初级审判和二级审判期间,在不利事件中只记录了一起死亡事件。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "所有初试候审候选人必须有一个HER2阳性肿瘤,由正FISH或IHC 3+证实。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ]
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "一审中PFS最长的病人是第1组,他活了3.5个月,没有病情发展或死亡。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "先前使用gabapentin或pregabalin进行治疗后,将被排除在二审之外,但不会被排除在初级审判之外。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19
        ],
        "Secondary_evidence_index": [
            12,
            13
        ]
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "初级审判比二审多记录4起不利事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X光、超声波、CT扫描或计量吸入器,包括初级审判和二级审判的干预",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "初级审判第1组第1组的100.0%至少遭受了一次危及生命的不利事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "初级试验组组群1比Eribulin和2组病人的Cyclopophosphamide剂量高于Doccexel",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "初级试验和二级试验正在以不同的剂量和不同的成果衡量方法研究同一种药物。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "第一次试验的结果显示,在手术前7天和乳腺癌手术后14天,Tamoxifen 每天32毫克po,平均将肿瘤直径减少40%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11
        ]
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "初级审判干预1的Denosumab剂量比二级审判干预1的Tamoxifen剂量高12倍。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "与二级审判相比,初级审判中的贫血病例总数较少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2,
            17
        ],
        "Secondary_evidence_index": [
            0,
            2
        ]
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "初级审判中的感染、不对称和误差案件多于二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3
        ]
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "在初级审判中,两个组群的Aes人和Aes人人数相同的报告",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23,
            24,
            25,
            26,
            27
        ]
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "接受初试的所有病人每3周至少得到20毫克MCS110。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "初级审判和二级审判都对病人组群进行环磷酰胺治疗。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "初级审判组的结果没有重大差异,但反光学组和控制组之间发现的一些差异导致二级审判。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17
        ],
        "Secondary_evidence_index": [
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20
        ]
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "初级审判的干预措施包括不同的药物,但通过同样的途径实施。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "获得ECOG分数为1的候选人有资格参加初级和二级审判",
        "Label": "Entailment",
        "Primary_evidence_index": [
            2
        ],
        "Secondary_evidence_index": [
            3
        ]
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "97%以上的二审和初级初审的病人没有遭受任何不利事件",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            12,
            13
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "初级审判的Cohort A和B在周期的同一时间对二次注射535LD V935的免疫注射进行同样的注射。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ]
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "与初级审判相比,第二次审判记录了11起未宣誓穿孔案件。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1
        ],
        "Secondary_evidence_index": [
            0,
            1
        ]
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "没有X光、心肺中转注射、CT扫描或包括初级审判和二级审判干预在内的MRIs的X光、心外注射、CT扫描或MRIs",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "第二次试验和第一次试验使用不同的结果计量和计量单位。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14
        ]
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "初级试验阶段的病人在整个学习期间将获得更高剂量的阿尔法利皮酸,每天最高为100毫克,最高为3次,而二级试验阶段第1组病人在整个试验期间将获得同样的Necitumumab剂量。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2
        ]
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "在初级试验中接受Lapatinib 1000 mg + Nab-Paclitaxel治疗的1/2以上病人,要么得到确认的完整反应(CR),要么得到确认的部分反应(PR)。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "乳腺癌患者呈雌激素阴性、原孕酮阴性、HER2-肿瘤,有资格接受初级试验",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9
        ]
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "在学习期间,大多数初级试用候选人患有某种饮食紊乱症",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            7
        ]
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "任何性别的患者只要有当地先进和/或转移的固态肿瘤证据,即可有资格参加初级审判的两个阶段。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            7,
            8,
            9,
            10,
            11,
            12
        ]
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "与快速、浅度呼吸小组病人相比,快速呼吸干预小组每天平均经历的热闪光较少。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15
        ]
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "酗酒的病人被排除在初级审判之外,但如果每天饮酒少于5杯酒精饮料,则有资格参加二级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            6
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13,
            14,
            15,
            16,
            17,
            18,
            19,
            20,
            21,
            22,
            23
        ]
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "对非小细胞肺癌或小细胞肺癌进行生理学/细胞学确诊的病人有资格接受初级试验。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            9,
            10
        ]
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "初级试验每天两次以150毫克的口服百草枯为口服百草枯治疗其一个病人组群,第二次试验则以脱氧细胞和HD-MTX治疗其病人。",
        "Label": "Entailment",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5
        ],
        "Secondary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7
        ]
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "TAK-228+Tamoxifen初级试验中治疗病人在TAK-228加Tamoxifen一个月后,基67表示值的细胞百分比下降了10%。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            0,
            1,
            2,
            3,
            4,
            5,
            6,
            7,
            8,
            9,
            10,
            11,
            12,
            13
        ]
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "对雌激素有严重厌食反应的病人,或对雌激素树脂有不作反应的病人,有资格接受初级审判。",
        "Label": "Contradiction",
        "Primary_evidence_index": [
            17
        ]
    }
}